Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Authors:
- Jieping LeiJLJieping Lei
- Anja RudolphARAnja Rudolph
- Kirsten B MoysichKMKirsten B Moysich
- Sajjad RafiqSRSajjad Rafiq
- Sabine BehrensSBSabine Behrens
- Ellen L GoodeEGEllen L Goode
- Paul Pd PharoahPPPaul Pd Pharoah
- Petra SeiboldPSPetra Seibold
- Peter A FaschingPeter A Fasching
- Irene L AndrulisIAIrene L Andrulis
- Vessela N KristensenVKVessela N Kristensen
- Fergus J CouchFCFergus J Couch
Open Access
- 10 February 2015
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 17 (1) , 18
Abstract
Introduction: Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen receptor (ER) negative breast cancer. To identify variants in immunosuppressive pathway genes associated with prognosis after adjuvant chemotherapy for ER-negative patients, we studied stage I-III invasive breast cancer patients of European ancestry, including 9,334 ER-positive (3,151 treated with chemotherapy) and 2,334 ER-negative patients (1,499 treated with chemotherapy). Methods: We pooled data from sixteen studies from the Breast Cancer Association Consortium (BCAC), and employed two independent studies for replications. Overall 3,610 single nucleotide polymorphisms (SNPs) in 133 genes were genotyped as part of the Collaborative Oncological Gene-environment Study, in which phenotype and clinical data were collected and harmonized. Multivariable Cox proportional hazard regression was used to assess genetic associations with overall survival (OS) and breast cancer-specific survival (BCSS). Heterogeneity according to chemotherapy or ER status was evaluated with the log-likelihood ratio test. Results: Three independent SNPs in TGFBR2 and IL12B were associated with OS (P C) (per allele hazard ratio (HR) 1.54 (95% confidence interval (CI) 1.22 to 1.95), P = 3.08 × 10−4) was not found in ER-negative patients without chemotherapy or ER-positive patients with chemotherapy (P for interaction A) with poorer OS (HR 1.50 (95% CI 1.21 to 1.86), P = 1.81 × 10−4), and rs2853694 (A > C) with improved OS (HR 0.73 (95% CI 0.61 to 0.87), P = 3.67 × 10−4). Similar associations were observed with BCSS. Association with TGFBR2 rs1367610 but not IL12B variants replicated using BCAC Asian samples and the independent Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer Study and yielded a combined HR of 1.57 ((95% CI 1.28 to 1.94), P = 2.05 × 10−5) without study heterogeneity. Conclusions: TGFBR2 variants may have prognostic and predictive value in ER-negative breast cancer patients treated with adjuvant chemotherapy. Our findings provide further insights into the development of immunotherapeutic targets for ER-negative breast cancer.Keywords
This publication has 49 references indexed in Scilit:
- Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer PatientsJournal of Breast Cancer, 2013
- Camouflage and sabotage: tumor escape from the immune systemCancer Immunology, Immunotherapy, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunityCancer and Metastasis Reviews, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- Immune surveillance: a balance between protumor and antitumor immunityCurrent Opinion in Genetics & Development, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986